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Abstract
Background: Bovine respiratory disease (BRD) continues to be great challenge in calf rearing units. The urgent
need to decrease the use of antibiotics and increase animal welfare in beef production has forced us to introduce
new preventive methods. Vaccinations could contribute to the solution, but the high incidence of BRD already at
an early age has made it difficult to introduce suitable vaccination programs. Challenge studies have shown
promising results in 3–14 day old calves vaccinated with intranasal BRD vaccine, but very few field trials are
available to assess the efficacy of the intranasal vaccines in field conditions. We evaluated the effect of one dose of
commercial intranasal vaccination on calf mortality, daily gain, and treatment incidence for BRD in one calf rearing
unit. In total, 497 calves (mean age 19 days) were included in our study, 247 of which were vaccinated at the time
of arrival to the unit and 250 served as negative controls (unvaccinated). Vaccinated and unvaccinated calves were
situated in separate compartments until weaning. Daily gain, treatment incidence, and mortality were recorded
until the calves were transported to the finishing unit, which averaged 154.5 days from arrival.
Results: Average daily gain over the complete study period was 1151.9 g/day (SD 137.9) for the vaccinated calves
and 1139.5 g/day (SD 135.9) for the unvaccinated calves. Intranasal vaccination combined with older arrival age (17
days or older) resulted in a higher daily gain (47.8 g/day) compared with unvaccinated calves (coef. 0.0478, p =
0.003). This association was not recorded in calves that were younger than 17 days upon arrival. Intranasal
vaccination was not significantly associated either with mortality (OR 0.976, p = 0.968) or treatment incidence for
BRD (OR 1.341, p = 0.120). In total, six vaccinated calves (2.43%) and six unvaccinated calves (2.40%) died during the
study period.
Conclusions: Vaccinating arriving calves with intranasal vaccine in the calf rearing unit did not decrease the
mortality or treatment incidence for BRD, but it significantly improved the weight gain in calves transported to the
unit at the age of 17 days or older.
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Background
Bovine respiratory disease (BRD) is the major cause of in-
creased morbidity and mortality in young calves [1–3].
BRD causes substantial economic losses for the cattle in-
dustry, and can also be seen as an animal welfare issue [4].
Several studies have demonstrated the negative economic
impact of increased mortality, treatment costs, and reduced
growth caused by BRD [5–7]. Moreover, high morbidity
rates lead to increased use of antibiotics, which is com-
monly associated with the emergence of antimicrobial re-
sistance [8]. Together with veal calf operating units in
Europe, calf rearing operations in Finland consume reason-
ably high levels of antibiotics [2, 9, 10]. A recent study pub-
lished in the Netherlands showed that antimicrobial
consumption rates in veal calf farms was several times
higher compared with pig and broiler farms [9]. Public con-
cern of animal welfare and emergence of antibiotic resist-
ance puts pressure on the industry to find new preventive
methods for improving animal health, and thus reduce the
use of antibiotics in the beef production chain [11].
BRD has a multifactorial origin, and can be caused by
several different pathogens either alone or combined
[12, 13]. Earlier studies have shown that BRD incidence
is highly dependent on environmental, individual, and
farm specific factors [1, 5]. Respiratory syncytial virus,
corona virus, parainfluenza type 3 virus, Pasteurella
multocida, Histophilus somni, Mannheimia haemolytica,
and Ureaplasma diversum are common respiratory path-
ogens around the world, and also the most frequently
found pathogens in cattle respiratory samples in Finland
[12–14]. Mycoplasma bovis was first isolated from a
Finnish cattle respiratory sample in 2012. Currently,
Finland is free from infectious bovine rhinotracheitis
and bovine viral diarrhea [14].
Beef production in Finland is mainly based on rearing
bull calves born in dairy farms on separate finishing farms
specialized in beef production. These bull calves are com-
monly either pure dairy breeds or dairy-beef crosses. They
are transported to separate rearing units at 10–30 days of
age. Unlike veal calf production in central Europe and
North America, calves in Finland are not slaughtered until
the age of 18–20months. Approximately two thirds of dairy
bull calves are first transported to specialized calf rearing
units where they are reared for 4–6months before trans-
portation to the specialized finishing farms. The remaining
calves are either transported to the finishing farms directly
after weaning, or to the integrated beef production farms
specialized for rearing unweaned calves to the slaughter
age. Prophylactic use of antibiotics is very rare in Finland.
Unlike in many other countries, vaccinations against
BRD are not commonly used in Finland. The growing size
of calf rearing units and rising incidence of BRD has forced
us to introduce new preventive methods. Vaccinating calves
more frequently against common respiratory pathogens in
the future could be one part of the solution. Since morbid-
ity and mortality rates are usually highest in the first weeks
after arrival to the calf rearing units [3, 15] and maternal
antibodies are known to have an inhibitory effect on paren-
terally administered vaccinations [16, 17], developing an ef-
fective vaccination program for young calves has been
problematic. This blocking effect has increased the interest
in introducing intranasally administrable vaccinations. Hill
and others [18] showed that 3–8 day old Holstein calves are
capable of developing mucosal immune response after in-
tranasal vaccination, even when maternal antibodies are
present. Other studies of intranasal vaccinations have also
shown promising results in young calves (3–14 days old)
vaccinated against common respiratory pathogens [19–21].
The short duration of immunity after one dose of intranasal
vaccination may set a requirement for subsequent booster
vaccines [19, 22]. Even though intranasal vaccinations have
not reduced the incidence of BRD in some studies, patho-
logical changes in lungs have been reduced [22, 23]. As
calves are transported to the rearing unit from numerous
farms, it would be more achievable to start vaccinating
calves at the time of arrival to the rearing unit, even though
the best vaccine effect would require vaccination already
before transportation. Despite the increased interest in in-
tranasal vaccinations, very few clinical trials are available to
prove their efficacy in field conditions.
The primary objective of this randomized field trial was
to evaluate the effect of a single dose of commercial intra-
nasal vaccination on treatment incidence for BRD, daily
gain, and calf mortality in one commercial calf rearing unit.
Results
Descriptive statistics
Upon arrival, 32.0% (n = 79) of the vaccinated calves and
30.4% (n = 76) of the unvaccinated calves were assessed to
have BRD (Table 1). The serum immunoglobulin G (IgG)
concentration at the time of arrival was below the refer-
ence value (10mg/ml) in 51.8% (n = 128) of the vaccinated
calves and 57.6% (n = 144) of the control calves (54.7%
(n = 272) of all calves). Overall, 23.3% (n = 116) of the
calves had serum amyloid A (SAA) values higher than the
reference value (178 μg/ml) [24]. The SAA reference value
was exceeded in 26.7% (n = 66) and 20% (n = 50) of the
vaccinated and unvaccinated calves, respectively. Differ-
ences in measured variables were not statistically signifi-
cant between vaccinated and unvaccinated calves.
During the study period, 318 (64%) calves received at
least one course of antibiotics. Specifically, 204 calves re-
ceived one, 102 calves received two, and 12 calves received
three antibiotic courses. Only three calves had antibiotics
administered three times for the same diagnosis. In total,
51% of the antibiotic courses were targeted against BRD,
22.6% against interdigital phlegmon, 17.2% against un-
known fever and 9.3% against other infections (umbilical
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inflammation, ear inflammation, arthritis). Only two
types of antibiotics were used during the study
period. Parenteral oxytetracycline was used in 68.6%
of the courses, and parenteral benzylpenicillin in
31.4%. A non-steroidal anti-inflammatory drug was
added to every antimicrobial course. On average, time
to first medication was 2.1 days longer in vaccinated
calves compared with unvaccinated calves (Table 2).
The difference in time to first medication was not
statistically significant between groups.
Table 1 Descriptive statistics of the 497 calves at the time of arrival
Total ± SD (min.-max.) Vaccinated ± SD (min.-max.) Unvaccinated ± SD (min.-max.)
n 497 247 250
Number of compartments 14 7 7
Sex: Male/female 467/30 231/16 236/14
Mean age at arrival/days 17 ± 4.9 (10–45) 16.7 ± 5.2 (10–45) 17.2 ± 4.6 (10–34)
Mean weight at arrival/kg 56.6 ± 8.8 (40–92) 56.8 ± 9.2 (40–92) 56.5 ± 8.4 (40–92)
Mean serum IgG a 10.2 ± 5.8 (0.7–33.9) 10.5 ± 5.9 (0.7–33.9) 9.8 ± 5.6 (0.7–27.7)
Mean serum SAAa 123.4 ± 81.1 (9.2–609.6) 127.1 ± 81.4 (9.2–436.8) 119.6 ± 80.7 (9.4–609.6)
Clinical condition a b 2.7 ± 2.0 (0–10) 2.7 ± 2.1 (0–10) 2.8 ± 2.0 (0–10)
BRD diagnosis a b 155 79 76
Breeds (n):
Ayrshire 191 87 104
Holstein 180 89 91
Finnish cattle 2 1 1
Dairy beef crosses 124 70 54
SD standard deviation, SAA Serum amyloid A, BRD Bovine respiratory disease,
a = Observed/measured at the first clinical examination, b = See the text for detailed description
Table 2 Descriptive statistics of the 497 calves over the complete study period (average 154.5 days)
Total ± SD (min.-max.) Vaccinated ± SD (min.-max.) Unvaccinated ± SD (min.-max.)
n 497 247 250
Average weight at weaning (kg) 83.4 ± 12.0 (40.5–126) 83.9 ± 12.6 (40.5–122) 82.8 ± 11.3 (52.5–126)
Average weight at the end of the study (kg) 233.7 ± 25.6 (126–310) 233.4 ± 26.2 (146–310) 233.9 ± 25.1 (126–302)
Daily gain, milk-feeding period (g/day) 630.7 ± 176.6 ((− 40)-1160) 641.7 ± 184.6 ((− 40)-1070) 619.6 ± 168.1 (150–1160)
Daily gain, complete study period (g/day) 1145.7 ± 136.9 (500–1520) 1151.9 ± 137.9 (670–1520) 1139.5 ± 135.9 (500–1460)
n (enrolled < 17 days of age) 261 139 122
Daily gain, (g/day) 1119.7 ± 131.0 (670–1460) 1109.3 ± 134.7 (670–1410) 1131.5 ± 126.2 (780–1460)
n (enrolled ≥17 days of age) 224 102 122
Daily gain, (g/day) 1176.0 ± 137.6 (500–1520) a 1209.9 ± 120.3 (880–1520) 1147.6 ± 145.0 (500–1460)
Clinical condition (2nd clin. exam) b 2.7 ± 1.9 (0–9) 2.7 ± 2 (0–8) 2.8 ± 1.8 (0–9)
BRD-diagnosis (2nd clin. exam) b 206 a 91 115
Antimicrobial treatments for 443 233 210
BRD 226 120 106
interdigital phlegmon 100 55 45
other inflammation 41 21 20
unknown fever 76 37 39
Oxytetracycline courses 304 157 147
Benzylpenicillin courses 139 76 63
Time to first medication (days) 20.7 ± 18.6 (0–93) 21.7 ± 19.2 (0–81) 19.6 ± 17.9 (0–93)
Premature death 12 6 6
SD standard deviation, BRD Bovine respiratory disease,
a = Variable significantly different between vaccination groups (p < 0.05), b = See the text for detailed description
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Average daily gain before weaning
Weight of the vaccinated calves was not significantly dif-
ferent than unvaccinated calves when measured at wean-
ing (p = 0.328) (Table 2). In the regression model,
vaccination was not significantly associated with daily
gain before weaning (coef. 0.028, p = 0.057). Female sex
of the calf (coef. 0.073, p = 0.033), older age at arrival to
the unit (coef. 0.185, p = 0.000), and positive diagnosis of
BRD at first clinical examination (coef. 0.040, p = 0.012)
were associated with better growth in the milk-feeding
period. Other independent factors in the model were
breed and serum SAA concentration. In total six calves
were excluded from the model (one due to missing
weight data and five due to untimely death during the
milk-feeding period).
Average daily gain during the complete study period
Average daily gain of the calves from arrival to the unit
until the end of the study period is presented in Table 2.
During the complete study period, vaccinated calves
gained an average of 12.3 g/day more than unvaccinated
calves. In the first final model, an interaction between
vaccination and age at time of arrival was detected
(Fig. 1). Thereafter, two different mixed regression
models were generated. One for calves younger than 17
days (n = 261) and another for calves 17 days or older
(n = 224) at the time of arrival to the unit. Vaccinated
calves had significantly better growth compared with un-
vaccinated control calves (coef. 0.048, p = 0.003) in the
model for calves 17 days or older at the time of arrival.
Other independent factors in the model positively asso-
ciated with growth were weight of the calf at arrival
(coef. 0.004, p < 0.001) and beef breed (coef. 0.051, p =
0.030). Female sex (coef. -0.103, p = 0.001) negatively af-
fected the growth. In the model for calves younger than
17 days at the time of arrival, vaccination did not have a
significant effect on growth (coef. -0.017, p = 0.239). The
only factor positively affecting growth in younger calves
was higher weight of the calf at the time of arrival to the
unit (coef. 0.005, p < 0.001). In total 12 calves were ex-
cluded from the models due to untimely death during
the study period.
BRD diagnosis at the time of the second clinical
examination
Vaccinated calves had lower odds ratios (OR) for BRD
diagnosis during the second clinical examination com-
pared with unvaccinated calves (OR = 0.639, p = 0.022).
BRD was diagnosed in 37.0% of vaccinated and 46.8% of
unvaccinated calves. Other variables in the logistic re-
gression model were age at arrival to the unit (OR =
1.627, p = 0.177), BRD diagnosis (OR = 1.510, p = 0.107),
and clinical score (OR = 1.048, p = 0.418) at the first clin-
ical examination. None of the other variables had statis-
tically significant effects on the dependent variable. In
total five calves were excluded from the model due to
untimely death during the milk-feeding period.
Treatments for BRD
In total, 34.2% of all calves were treated once for BRD
(31.2% of unvaccinated, 37.3% of vaccinated calves). 5%
were treated two times (4.4% unvaccinated, 5.7% vacci-
nated) and 0.4% were treated three times (0.8% unvac-
cinated, 0.0% vaccinated) for BRD during the study
Fig. 1 Interaction between intranasal vaccination and calves’ age at arrival to the calf rearing unit. In total, 247 calves were vaccinated and 250
calves served as negative controls (unvaccinated). Predicted values for daily gain during the whole study period are estimates from the
regression model
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period. From vaccinated calves, 42.9% were treated for
BRD at least once during the study period; for the un-
vaccinated calves, the total was 36.4%. However, the dif-
ference between vaccinated and unvaccinated calves was
not statistically significant (OR = 1.341, p = 0.120) ac-
cording to the mixed regression model that tested the
probability of the calf to be treated against BRD at least
once during the study period. Other factors preserved in
the model were serum IgG and SAA levels at arrival to
the unit (OR = 0.968, p = 0.058; OR = 1.214, p = 0.147),
calf weight at arrival to the unit (OR = 0.984, p = 0.154),
BRD diagnosis (OR = 1.337, p = 0.247), and clinical con-
dition at arrival to the unit (OR = 1.071, p = 0.224). None
of these factors had statistically significant effects on the
chance to be treated for BRD. All the study calves (n =
497) were included in the model.
Mortality
Mortality during the study period was 2.41%. Six (2.43%)
vaccinated and six (2.40%) unvaccinated calves died dur-
ing the study period. Three whole calves and two lung-
heart packages were sent to necropsy to determine the
cause of death. Pneumonia was determined as the cause
of death in two control calves, polyarticular arthritis
combined with omphalitis was the cause of death in one
vaccinated calf, and unidentified gastrointestinal disease
was the cause of death in one control calf. The cause of
death could not be determined for one necropsied calf.
The remaining seven dead calves were not necropsied.
The mean time spent in the unit before their untimely
death was 83.3 days (SD 51.2, range = 28–180). The dif-
ference in mortality between vaccinated and unvaccin-
ated calves was not statistically significant in the logistic
mixed regression model (OR = 0.870, p = 0.817). Only
one other factor preserved in the model was the number
of antimicrobial treatments in addition to the confound-
ing factors of sex and breed. The higher number of anti-
microbial treatments during the rearing period
significantly increased the odds that the calf would die
during the study period (OR = 2.645, p = 0.006). All the
study calves (n = 497) were included in the model.
Discussion
In this study, BRD morbidity, average daily gain, and
mortality of the calves vaccinated with intranasal BRD
vaccine (Rispoval RS + Pi3 Intranasal, Zoetis) were com-
pared with unvaccinated calves in one commercial calf
rearing unit in Finland. Vaccination combined with older
arrival age (17 days or older) resulted in significantly
greater daily gain (on average 47.8 g) compared with un-
vaccinated calves. This difference was not recorded in
calves that arrived when they were younger than 17 days.
In our study, all the vaccinated calves were vaccinated
one to three days after arrival. This finding suggests that
younger calves are not capable of responding to the vac-
cination as effectively as older calves. Further studies are
needed to determine if this is a result of the younger
calves having an immature immune system, or inhibitory
effects of maternal antibodies. Vaccination also showed
a trend towards increasing daily gain during the milk-
feeding period independent of age at the time of arrival.
Additionally, vaccination lowered the odds ratio for BRD
diagnosis at the second clinical examination.
The efficacy of intranasal vaccinations has been dem-
onstrated in many experimental challenge studies, but
very few clinical field trials are available [19, 20, 25, 26].
Ollivett and others [23] conducted a field trial in three
dairy herds, where they intranasally vaccinated young
calves for bovine rhinotracheitis, parainfluenza-3 virus
and respiratory syncytial virus. The current study was
conducted in a calf rearing unit, and it differed from the
challenge studies in several ways. In our study, maternal
antibody levels in calf serum displayed variation at the
time of vaccination, and calves were naturally exposed to
a wide range of pathogens. We knew from earlier studies
and reports that bovine respiratory syncytial virus and
parainfluenza-3 virus are rather common pathogens in
Finnish cattle, thus we were quite confident that these
pathogens would be present in the large rearing unit
used in our study [12, 14, 27]. Here, we studied the effi-
cacy of the vaccination under field conditions, which
have probably also led to BRD cases caused by patho-
gens other than those included in the vaccine. The out-
comes examined in our study were daily gain before
weaning, daily gain during the complete study period,
BRD diagnosis during the second clinical examination
(at the time of weaning), number of antimicrobial treat-
ments for BRD, and mortality during the study period.
Manufacturers recommend to vaccinate calves already
ten days before a period of stress or high infection risk
such as re-grouping or transportation, in order to
achieve an optimal result. In practice, this is difficult to
implement because the calves often have multiple ori-
gins, and dairy farmers are rarely motivated to vaccinate
calves that are shortly leaving the farms. A more feasible
practice could be to vaccinate calves at the time of ar-
rival to the calf rearing unit (or immediately after), as we
did in our study. We were aware that this may lead to
decreased efficacy because the calves might get infected
already before the vaccination or before the immunity
has been successfully developed. According to our
knowledge, there are no published efficacy studies of a
similar intranasal vaccination protocol in the prevention
of BRD in commercial calf rearing units. Nevertheless,
the practice is commonly used in some European coun-
tries [28].
In our study, farm personnel used different overalls
and boots in all compartments for the first ten days
Sandelin et al. BMC Veterinary Research           (2020) 16:73 Page 5 of 10
following vaccination to avoid the contamination of un-
vaccinated calves from potential nasal shedding by vacci-
nated calves. According to the vaccine manufacturer’s
data, the shedding of BRSV and PI-3 V is possible up to
11 and 7 days after vaccination, respectively. Some stud-
ies have reported even longer shedding times [29]. Ac-
cording to this, risk of spreading vaccine viruses from
vaccinated calves to unvaccinated calves via contami-
nated overalls or boots is possible even after ten days
post vaccination. The authors are aware of this risk but
it is considered minimal.
BRD diagnosis at the first clinical examination was as-
sociated with increased growth in the milk-feeding
period. This positive association is hard to explain. The
calf transportation system in Finland is based on the rule
that only healthy animals are accepted for transporta-
tion. A decision is made by the dairy farmer and edu-
cated driver, but it is still a subjective decision and mild
signs of a disease can be easily missed when a calf is
otherwise apparently healthy. Bigger calves and those
with higher growth potential are probably more likely to
be transported despite the sickness, whereas small, older,
and lower growth potential calves might be more readily
excluded. This might lead to a situation where slightly ill
calves with high growth potential are over-represented
in the study population at the time of arrival.
Our BRD diagnosis was based on the scoring system
used by Love and colleagues [30]; the only difference
was that we used stethoscope auscultation rather than
visual inspection to evaluate respiratory sounds, as was
done in the original scoring system. The assessment of
abnormal respiration based on audio sounds rather vis-
ual cues might have led to our finding of higher scores
compared with the original scoring system. We also used
a clinical score to describe the overall health of the calf
at the time of clinical examination. Specifically, this was
calculated by summing up the findings of the clinical
examination. To our knowledge, this method is not
based on any scoring system. Nevertheless, we consid-
ered it useful to account for disease conditions other
than respiratory diseases when assessing the health of
calves.
Vaccination was the only factor to significantly de-
crease the risk of BRD diagnosis in the second clinical
examination. Using ultrasonography for the more accur-
ate detection of lung lesions would have given more in-
formation on the actual status of the lungs. In a recent
clinical trial, the intranasal vaccination lowered the odds
of lung consolidation compared with unvaccinated
calves, even though overall treatment for BRD was not
reduced [23]. A similar effect might explain why the
number of treatments against BRD was not reduced in
the current study, even though the diagnosed BRD cases
in the second clinical examination were reduced.
Thompson and others [6] showed the association be-
tween lung lesions and decreased daily gain in slaugh-
tered feedlot cattle. In the same study, they also
demonstrated the existence of subclinical BRD by show-
ing that lung lesions were presented in 38.5% of the ani-
mals never treated for BRD. This could also explain the
enhanced daily gain in vaccinated calves in our study,
even though the treatments for BRD were not reduced.
Further studies are needed to prove this theory.
There was a trend towards high serum IgG at the time
of arrival reducing the probability of the calf being
treated for BRD. A similar association between low
serum IgG levels and higher morbidity has also been
presented in previous studies [31, 32]. To the best of our
knowledge, there are no studied reference values for
serum IgG levels for calves 2–4 weeks old. For two day
old calves, 10 mg/ml is commonly used as the minimum
level for successful passive transfer, but earlier studies
have shown that the amount of IgG in serum decreases
slowly after birth, with a half-life of 28.5 days [33]. In the
current study, 44.1% of the calves with low serum IgG
(< 10mg/ml on arrival; mean age 17 days) were treated
at least once against BRD, compared with 34.2% of the
calves with high serum IgG (> 10mg/ml at arrival, mean
age 17 days). This supports earlier findings that have
demonstrated how successful passive transfer of mater-
nal antibodies is important for the health of the calf [34].
Of the arriving calves, 23.3% had serum SAA higher
than the reference value < 178 mg/ml suggested by
Seppä-Lassila and colleagues [24]. Calves with higher
serum SAA concentration gained weight slower than
calves with lower concentrations, as also reported in
earlier studies [2]. Elevated concentrations of serum
SAA may be normal in calves younger than two weeks
old, or they may be a reflection of some existing inflam-
mation already present at the time of arrival [24]. Ac-
cording to clinical examination data, 12.6% of the
arriving calves suffered either healing or acute inflamma-
tion of the umbilicus.
The results of this study are promising even they can-
not be adapted directly to all calf rearing units due to
differences in pathogen profiles. The large number of
different origin farms may even cause the pathogen pro-
file variation between the consecutive batches of arriving
calves. According to the results of this study, it would be
worth considering transporting slightly older calves to
the calf rearing units where the intranasal vaccination is
used.
Conclusions
Administration of a single intranasal dose of a commer-
cially available vaccination significantly increased daily
gain in calves that arrived at the calf rearing unit at the
age of 17 days or older. Vaccination did not reduce the
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number of calves medicated for BRD, but it lower the in-
cidence of diagnosed BRD at the time of weaning. A
higher number of antimicrobial treatments during the
rearing period significantly increased the odds of prema-
ture death.
Methods
Study population and study design
The randomized field trial was designed to test the effi-
cacy of a single dose of commercial intranasal vaccine in
one calf rearing unit. During the study, 247 calves were
vaccinated at the time of arrival, and 250 calves served
as negative controls (unvaccinated). Clinical examination
and sample collection were carried out on all calves at
two times (at arrival and weaning). Study calves were
vaccinated during the first clinical examination. The
study period started on the day of first clinical examin-
ation and lasted until the day when calves were trans-
ported to the finishing unit (average 154.5 days, SD 4.7).
Daily gain was calculated during the period from arrival
to weaning (milk-feeding period), and again from arrival
to transportation to finishing unit (complete study
period). Medications were recorded for the whole study
period. Blood samples were analyzed to detect possible
low serum IgG levels and high SAA levels at the time of
enrolment. Normal operation cycle of the calf rearing
unit remained throughout the study period and after
study calves were transported to the feedlot for finishing
cattle as usual. None of the calves were euthanized be-
cause of the study. Study design was approved in ad-
vance by the Animal Experimental Board of the Regional
State Administrative Agency in Finland (ref. number:
ESAVI/9788/04.10.07/2016).
The study was carried out in four similar milk-feeding
compartments of one privately owned calf rearing unit
located in southwestern Finland, between January 2017
and January 2018. The entire unit was comprised of six
separate milk-feeding compartments and two larger sep-
arate uninsulated compartments for older calves. The
unit was operated as an all-in all-out system, such that
all six milk-feeding compartments were emptied, washed
and disinfected prior to every arrival of new calves. The
unit was confirmed to be free of Mycoplasma bovis. A
milk replacer (Primo powermix, Suomen Rehu Oy,
Finland) was dispensed by an automatic milk-feeding
system (in total 33 kg/calf during the milk-feeding
period), and all the calves had free entry to silage and
concentrates (Primo Kasvatus 1, Suomen Rehu Oy,
Finland). Each compartment contained one large pen
with a solid floor feeding area and peat/straw bedding
on the resting area. All compartments were insulated
and had separate ventilation systems based on automatic
exhaust fans. After 43 days of milk-feeding, calves were
gradually weaned and then merged with the calves from
the other compartments into one larger uninsulated
compartment. Unlimited mixed feed was supplemented
with 2 kg of grated barley/rapeseed mixture was offered
to all calves daily from three weeks after weaning until
the end of the study period (total concentrate percent
around 55).
All calves used in this study (n = 497) were transported
to the unit in seven batches (average 71 calves per batch,
range = 68–76). All four similar milk-feeding compart-
ments (average 36 calves each) were refilled every two
months over a two-week time period. This cycle re-
peated four times, except in the last cycle (seventh
batch) when only two compartments were included in
the study. Upon arrival after transportation, calves were
randomly allocated to two different compartments that
were filled simultaneously. Calves in one of these two
compartments were randomly selected to serve as nega-
tive controls, whereas calves in the other compartment
were vaccinated once with commercial intranasal vaccin-
ation (Rispoval RS + Pi3 Intranasal, Zoetis) consisting of
a modified live bovine respiratory syncytial virus (BRSV)
and parainfluenza type 3 virus (PI-3 V). Vaccination was
performed according to manufacturer’s guidelines. In
total seven compartments of vaccinated calves and seven
compartments of unvaccinated calves were included in
the study. At the first clinical examination, sample col-
lection and possible vaccination was performed on each
calf by a veterinarian one to three days after arrival to
the unit. During the study, the farmers remained blind
regarding the vaccination status of the group. For the
first ten days following vaccination, different overalls
and boots were used in all compartments to avoid con-
tamination of unvaccinated calves from potential nasal
shedding by vaccinated calves.
Data and sample collection
Clinical examination and sample collection was per-
formed on all calves one to three days after arrival to the
unit (mean age 19.0 days, SD 5.0) and repeated 40–44
days later (mean age 59.3 days, SD 5.3) at the time of
weaning. Descriptive data of the calves enrolled in the
study is presented in Table 1. All the calves were grad-
ually weaned by rearing day 43. The calves’ weight was
measured three times during the study period: At the
time of arrival to the unit, at the time of second clinical
examination, and right before transportation to the fin-
ishing unit. Clinical examination included measurement
of body temperature, auscultation of heart and lungs,
measurement of the respiratory rate and heart rate, in-
spection of the nose and eyes for discharge, recording of
ear position, palpation and inspection of umbilicus,
joints and hooves. Appearance of cough or diarrhea was
also recorded. Each calf was scored 1–3 based on gen-
eral appearance. The clinical examination data was used
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to calculate a clinical condition score and BRD score
for each calf. The clinical condition score was calcu-
lated by summing up the scores of the clinical exami-
nations (Table 3). BRD was diagnosed and scored
according to the third of the three scoring systems of
Love and colleagues [30] (Table 4). All clinical exami-
nations were done by veterinarians from the research
group.
After the clinical examinations were performed, a
blood sample was obtained by venipuncture of the vena
jugularis with a vacuum system (9 ml Z Serum Clot Ac-
tivator, Vacuette, Austria). Before releasing the calf to
the pen in vaccination groups, a single-use plastic nasal
cannula (Zoetis) was used to administer 1 ml of vaccine
to the nostril of the calf. Calves were examined in
batches such that one group of vaccinated and unvaccin-
ated calves were examined on the same day. Examina-
tions always started with the unvaccinated group to
avoid contamination from potential nasal shedding. Vac-
cination was not repeated on the second visit.
Throughout the study period, signs of diseases,
treatments, and mortality of the calves were observed
and recorded on a daily basis by the farmer. Sick
calves were treated by the farmer according to the in-
structions of the farm’s contract veterinarian. Medica-
tion for BRD was started if two or more of the
following signs were recognized: increased body
temperature (> 39.7 °C), signs of depression, loss of
appetite, rapid or difficult breathing. The primary
medication for respiratory inflammation was a com-
bination of parenteral oxytetracycline and parenteral
non-steroidal anti-inflammatory drug (NSAID). For
interdigital phlegmon or umbilical inflammation, a
combination of parenteral benzylpenicillin and NSAID
was used as the primary medication. The date of
treatment together with all the observed signs (body
temperature, signs of depression, inappetence, rapid
or difficult breathing, coughing, possible eye or nasal
discharge, diarrhea, interdigital phlegmon, any other
signs of disease) and medicines used were precisely
recorded. If the calf was seriously ill and untreatable,
herd veterinarian euthanized the calf due welfare rea-
sons. First, the calf was tranquilized with 0.2 mg/kg
xylazine (Nerfasin vet 20 mg/ml, Le Vet B. V,
Netherlands), and thereafter 140 mg/kg of product
containing pentobarbital sodium and phenytoin so-
dium (Euthasol vet 400 mg/ml, Le Vet B.V). Both
products injected into the jugular vein. When pos-
sible, necropsy was done to calves that died or eutha-
nized during the study period.
Table 3 Summary of clinical examination scoring parameters for clinical condition score calculations
Score
Clinical sign 0 1 2
Rectal temperature (̊C) < 39.2 – ≥ 39.2
Respiratory rate < 45 ≥ 45
Respiratory sounds Normal Minor chances Major chances
Ear position/Head tilt Normal – Ear droop/head tilt
Nasal discharge None Watery discharge Cloudy discharge
Ocular discharge None Watery discharge Cloudy discharge
Umbilicus Normal Thickened Inflamed
Joints Normal Arthritis in one joint Polyarthritis
Bruises in joint area None One joint Two or more joints
Interdigital phlegmon None One claw Two or more claws
Feacal consistence None Loose Watery diarrhea
Spontaneous cough None – Coughing spontaneously
Table 4 BRD-scoring parameters for calves
Clinical sign Level Score
Cough None or induced cough 0
Spontaneous cough 2
Nasal discharge None 0
Any 4
Ocular discharge None 0
Any 2
Ear position Normal, ear flick or head shake 0
Ear droop or head tilt 5
Rectal temperature (̊C) < 39.2 0
≥ 39.2 2
Abnormal respirationa Absent 0
Present 2
aAuscultation was performed by using a stethoscope
Calves were categorized as BRD positive if their total score was ≥5 (modified
Love et al. 2014)
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Analysis of blood samples
After the blood samples were collected, they were trans-
ported to the laboratory and stored in a Styrofoam box
with cooling elements. In the laboratory, blood samples
were centrifuged at 3500 rpm for 15min to separate the
serum, which was then isolated and stored at − 20 °C in
2 ml tubes (Sarstedt, Germany) until analyzed for bovine
IgG and SAA concentrations. IgG of the serum samples
was analyzed using a commercial ELISA kit (Bovine IgG
ELISA Quantitation Set Cat. No. E10–118, Bethyl La-
boratories, Inc., Montgomery, TX, USA) with dilutions
1:200000 and 1:40000 and detection ranges 1.56–100
mg/ml and 0.31–20 mg/ml, respectively. Analysis was
done according to the manufacturer’s instructions.
Serum SAA concentration was measured with a com-
mercially available solid phase sandwich ELISA kit
(Phase TM Range Multispecies SAA ELISA kit, Tridelta
Development Ltd., Ireland) according to the manufac-
turer’s instructions for bovine samples. Dilutions of 1:
500, 1:1000 and 1:4000 were used with detection ranges
9.4–150 μg/ml, 18.8–300 μg/ml and 75.2–1200 μg/ml,
respectively.
Statistical analysis
According to the sample size calculations, 250 controls
and 250 vaccinated calves were needed to detect a differ-
ence of 10% in treatment rate between study groups
(power 0.9). A p-value < 0.05 was considered statistically
significant. Independent t-tests were used to compare
the weight, age, clinical condition scores, serum IgG and
SAA concentrations of the calves in different vaccination
groups at the time of arrival. Descriptive data is pre-
sented in Table 1.
Linear mixed regression models were used to study
the association between intranasal vaccination and daily
gain of the calves during the milk-feeding period and the
complete study period. Because of the interaction de-
tected between the calf age at arrival and vaccination
(Fig. 1), two separate models were used to evaluate the
association between vaccination and daily gain during
the complete study period. One model was used for
calves 17 days or older at the time of arrival, and another
model for calves younger than 17 days. Additionally,
three logistic mixed regression models were used to
study the association between intranasal vaccination and
BRD diagnosis at the second clinical examination (0/1),
treated for BRD during the study period (0/1), and death
of the calf before transportation to the finishing unit (0/
1). The transportation batch was used as a random fac-
tor in all models. In addition to vaccination status (vac-
cinated or unvaccinated), we studied several potential
explanatory covariates. Nominal variables included sex
(male, female) and breed of the calves (Ayrshire, Hol-
stein, Dairy-beef crosses) and BRD diagnosis at the first
clinical examination (0/1). Continuous variables included
age and weight of the calves at arrival, clinical score, and
serum IgG and SAA concentration at the time of the
first clinical examination. Age at arrival and SAA con-
centration were log-transformed to achieve normal dis-
tribution (and better suitability for the models). The
number of antimicrobial treatments per calf was tested
in models with outcome variables such as daily gain and
mortality to control the possible confounding effect on
the outcomes. Moreover, the confounding effect of sex
and breed was tested in all models if that variable was
not already included in the model (e.g. in the case of
univariate analyses). A change greater than 20% in vari-
able coefficients or odds ratios was defined as confound-
ing. All the biologically meaningful two-way interactions
between vaccination and fixed factors were tested. All
statistical analyses were performed in Stata/MP 14.1 for
Windows (StataCorp LP, Texas, USA).
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